Tuesday, 02 January 2024 12:17 GMT

Swiss Pharma Firm Sandoz Invests $440 Million In Slovenia


(MENAFN- Swissinfo) Sandoz is expanding its presence in Slovenia. The Basel-based generics giant has launched the construction of a new biosimilars production centre in Brnik at a cost of $440 million (CHF349 million). This content was published on July 2, 2025 - 14:12 1 minute Keystone-SDA
  • Français fr Sandoz investit 440 millions de dollars en Slovénie Original Read more: Sandoz investit 440 millions de dollars en Slovéni

+Get the most important news from Switzerland in your inbox

The announcement brings current and planned investments in the small Alpine country to more than $1.1 billion by 2029, according to a press release issued on Tuesday by the specialist in generic and biosimilar treatments. These include a new biosimilars production centre in Lendava and a development centre in the capital, Ljubljana.

Sandoz intends to take advantage of an“unprecedented market opportunity”, with patent expiries expected to reach $222 billion over the next ten years. The Group believes it is the leading foreign direct investor in the European country.

More More Swiss pharma's big bet on Slovenia

This content was published on Feb 9, 2024 As Swiss companies Novartis and Sandoz shift to complex, expensive medicine, they are increasingly dependent on the tiny Balkan nation of Slovenia.

Read more: Swiss pharma's big bet on Sloveni

MENAFN02072025000210011054ID1109753191


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search